Skip to main content

News Archive

News Archive - Yadira Galindo

Vulnerability Identified for Subtypes of Glioblastoma

November 30, 2017

Glioblastoma, the most common and aggressive form of brain cancer, typically fails to respond to treatment or rapidly becomes drug resistant. In a paper published online in the journal Cancer Cell on November 30, University of California San Diego School of Medicine researchers identified a strategy that pinpoints a genetically distinct subpopulation of patients with glioblastoma that is particularly sensitive to drugs like cilengitide that target a cell adhesion receptor known as integrin αvβ3.

Immunotherapy Research for Head and Neck Cancers Gets Boost from V Foundation Grant

November 27, 2017

A team of University of California San Diego School of Medicine and Moores Cancer Center researchers studying new drugs designed to break resistance to cancer immunotherapy has been awarded a V Foundation for Cancer Research translational grant of $600,000 over three years.

A New Strategy for Prevention of Liver Cancer Development

November 14, 2017

Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective treatments or drugs. However, an unexpected finding made by a team of University of California San Diego School of Medicine researchers sheds light on the development of a new strategy for prevention of liver cancer.

Women Needed to Contribute to WISDOM for Breast Cancer Screening

November 6, 2017

The five University of California medical centers, including Moores Cancer Center at UC San Diego Health, have joined together to recruit 100,000 women in California to be part of WISDOM: a clinical trial to uncover whether annual mammograms are the best way to screen for breast cancer, or whether a more personalized approach could deliver better results.

Machine Learning Detects Marketing and Sale of Opioids on Twitter

October 25, 2017

Using advanced machine learning, a cross disciplinary team of University of California San Diego researchers developed technology that mined Twitter to identify entities illegally selling prescription opioids online.

Exposure to Glyphosate, Chemical Found in Weed Killers, Increased Over 23 Years

October 24, 2017

Analyzing samples from a prospective study, University of California San Diego School of Medicine researchers found that human exposure to glyphosate, a chemical widely found in weed killers, has increased approximately 500 percent since the introduction of genetically modified crops.

Powered by Chemo: Patient with Advanced Pancreatic Cancer Tackles Ironman Triathlon

October 10, 2017

Despite a diagnosis of stage IV pancreatic cancer and ongoing chemotherapy, Mike Levine boarded a plane this past weekend destined for Kona, Hawaii, where he will compete in one of the most grueling of physical competitions: the Ironman World Championship. Cheering him on will be his wife Jan, friends and Paul Fanta, MD, a pancreatic cancer expert with Moores Cancer Center at UC San Diego Health who has been treating Levine since 2016.

DNA Mutations Shed in Blood Predicts Response to Immunotherapy in Patients with Cancer

October 1, 2017

In a first-of-its-kind study, University of California San Diego School of Medicine researchers report that a blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies.

Exosomes are the Missing Link to Insulin Resistance in Diabetes

September 21, 2017

Chronic tissue inflammation resulting from obesity is an underlying cause of insulin resistance and type 2 diabetes. But the mechanism by which this occurs has remained cloaked, until now. In a paper, University of California San Diego School of Medicine researchers identified exosomes — extremely small vesicles or sacs secreted from most cell types — as the missing link.

Drug Combination May Improve Impact of Immunotherapy in Head and Neck Cancer

September 21, 2017

Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy’s effectiveness.
Category navigation with Social links